Small Case Series of Gastric Stimulation for the Management of Transplant-Induced Gastroparesis

Enterra®Therapy: gastric neurostimulator for gastroparesis

“…Since then, multiple small, nonrandomized, unblinded clinical trials have been performed demonstrating a variable efficacy that ranges from 50 to 87%. The main areas of improvement include total symptom score severity, vomiting and nausea [2,26,[31][32][33][34][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55]. Studies describing no benefit have also been published.…”

“…The studies presented in TaBle 1 demonstrate the clinical trials and most significant findings. The methods used to evaluate and quantify symptoms, as well as definitions for improvement, vary between studies, making it difficult to interpret the data uniformly [2,26,[31][32][33]36,[40][41][42][43][44][45][46][47][48][49][50][51][52][53][55][56][57][58]. Not all of the clinical trials documented the Enterra settings (frequency, energy and on/off periods) that were used, and whether or not these settings were Jones et al Forster et al Cutts et al [42] Forster et al [44] McCallum et al Four out of seven off feed tubes [45] Oubre et al …”

“…GES has also been attempted in a small series of post-transplant gastroparesis with promising results [53].…”

Recomendaciones SORECAR. Rehabilitación en el trasplante pulmonar

“…La hipertensión arterial, la insuficiencia renal, la dislipemia, las cataratas, la osteoporosis, las necrosis óseas avasculares de cadera, las polineuropatías y los problemas gastrointestinales, como la gastroparesia, son efectos secundarios relativamente frecuentes de los inmunosupresores necesarios en el TP 60,61 .…”

Endoscopic Botulinum Toxin Injection for the Treatment of Diabetic Gastropathy in Pancreas and Islet-cell Transplant Patients

“…For example, improvement in gastric motility can facilitate the absorption of immunosuppressants, such as tacrolimus, which in theory, could subsequently increase its bioavailability and result in toxicity requiring a dose reduction. 5 In refractory cases when dietary and medical therapy are unsuccessful, endoscopic and surgical procedures are available, such as the insertion of a feeding jejunostomy tube, 6, 7 the use of implantable gastric electrical stimulator devices, 8,9 or major surgical resection, such as partial or total gastrectomy. 10 We report the use of endoscopic botulinum toxin (Botox, Allergan, Inc., Irvine, CA, USA) injection in patients with symptomatic DGE secondary to diabetic gastroparesis, specifically in patients who have undergone or are awaiting either pancreas or islet-cell transplantation.…”